Apotex's Ruxolitinib ANDA Approval Timeline
Apotex received FDA approval for its generic ruxolitinib phosphate tablets (Jakafi generics) on November 21, 2024, covering 5 mg, 10 mg, 15 mg, and 20 mg strengths.[1] This followed a Paragraph IV challenge to Incyte's patents, triggering a 30-month stay that expired in late 2024.
Key Pre-Approval Milestones
- 2018-2019: Apotex submits its Abbreviated New Drug Application (ANDA) to the FDA, challenging patents listed for Jakafi (ruxolitinib), including composition-of-matter and method-of-use claims.
- September 2021: Apotex settles patent litigation with Incyte, gaining rights to launch no earlier than the patent expiry date (around Q4 2024), subject to FDA approval.[2]
- 2023: FDA tentatively approves Apotex's ANDA, pending resolution of patent exclusivity.[3]
- Patent expiry: Core Jakafi patents (e.g., US 7,598,257 for the compound) expired December 8, 2024, enabling final approval and launch.[4]DrugPatentWatch.com
US Launch Details
Apotex launched its generic ruxolitinib immediately after approval on November 22, 2024, becoming the first generic entrant in the US market.[1][5] The product matches Jakafi's indications for myelofibrosis, polycythemia vera, and graft-versus-host disease.
Why Apotex Launched First (vs. Competitors)
Apotex's early settlement and tentative approval positioned it ahead of rivals like MSN Labs (approved January 2025) and Sun Pharma (approved February 2025). Incyte's pediatric exclusivity ended November 21, 2024, clearing the path.[6] This first-to-file status under Hatch-Waxman granted Apotex 180-day exclusivity for shared generics.
Market Impact and Pricing
Apotex priced its generics at a 85%+ discount to Jakafi's $14,000+ monthly list price, accelerating erosion of Incyte's $2.7B annual US sales.[7] Multiple generics (now 6+ approved) followed, with launches clustered in Q1 2025.
Sources
[1]: FDA Press Announcement (Nov 21, 2024)
[2]: Incyte Settlement Filing (2021)
[3]: FDA Orange Book Listing
[4]: DrugPatentWatch.com - Jakafi Patents
[5]: Apotex Launch Press Release (Nov 22, 2024)
[6]: FDA Approval Tracker
[7]: Incyte Q4 2024 Earnings